Phosphodiesterase

Phosphodiesterases (PDEs) are a family of enzymes that hydrolyze cyclic nucleotides (cAMP and cGMP), regulating intracellular signaling cascades. PDE5, the isoform targeted by sildenafil and tadalafil, is best known for its role in erectile dysfunction pharmacotherapy, but emerging evidence connects PDE inhibitors to broader biological effects including microbiome modulation.

Genomic and metabolomic analyses of sildenafil-treated patients reveal systemic metabolic shifts beyond the expected vascular effects, including altered bile acid and amino acid profiles that intersect with gut microbial metabolism (^{[1]Rocca 2020 — Evaluation of Serum/Urine Genomic and Metabolomic Profiles to Improve the Adherence to Sildenafil Therapy in Patients with Erectile DysfunctionMaria Santa Rocca, Alessia Vignoli, Leonardo Tenori et al. · 2020Open reference 1 ↓}).

Bioinformatic approaches to erectile dysfunction have identified PDE-related pathways as nodes in networks connecting vascular function, Metal-Driven Inflammation, and microbial metabolite signaling (^{[2]Singh 2024 — Bioinformatics-Driven Insights for Erectile Dysfunction TreatmentVinay Kumar Singh · 2024Open reference 2 ↓}).

In bacteria, phosphodiesterases serve as metal-sensing signaling enzymes, with metal cofactor availability (zinc, manganese) directly regulating cyclic-di-GMP turnover and, consequently, biofilm formation decisions. This positions PDEs at the intersection of host pharmacology and microbial ecology.